Management of Olanzapine-Induced Sinus Tachycardia

Initial Assessment and Management

• The American College of Cardiology recommends against using rate-control agents initially for olanzapine-induced sinus tachycardia, as it is a compensatory response to drug toxicity, not primary sinus tachycardia requiring suppression 1
• The American College of Cardiology advises against treating olanzapine-induced sinus tachycardia with adenosine or aggressive rate control with beta-blockers or calcium channel blockers, as the tachycardia is compensatory and will resolve with drug clearance 1

Special Considerations

• In cases of severe olanzapine intoxication, the use of flumazenil, a GABA receptor antagonist, has been reported to reverse symptoms within minutes, although this is an off-label use with limited evidence 1

Management of Olanzapine-Induced Sinus Tachycardia

Monitoring and Supportive Care

• The American College of Cardiology recommends continuous telemetry monitoring to assess for hemodynamic instability and track resolution of tachycardia as the drug clears, with serial ECGs every 4-6 hours initially, then daily until stable, to monitor QRS duration and QTc interval 2, 3
• Maintain adequate hydration with IV fluids to support hemodynamics and renal perfusion, and monitor urine output to ensure at least 0.5 mL/kg/hour, checking twice daily 4, 5
• Assess for hypotension; if present despite IV fluid bolus, this indicates severe toxicity requiring intensive monitoring 5